Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
默沙東首席執行官談Winrevair的批准、肥胖藥物、健康成本
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphic.)
默沙東董事長兼首席執行官Robert M. Davis討論了美國批准Winrevair的情況,Winrevair是一種治療罕見、危險的高血壓的新療法。戴維斯在彭博電視臺發表講話時還評論了默克開發的抗肥胖藥物和醫療費用。(對視頻進行了編輯,刪除了不正確的圖形。)